What is the typical dosing for Invega Sustenna?
Invega Sustenna, an injectable antipsychotic medication, is typically administered by a healthcare professional. The usual starting dose is 234 mg intramuscularly on day 1, followed by a dose of 156 mg two weeks later, and then a maintenance dose of 156 mg every four weeks thereafter [1]. However, doses can be adjusted by a prescriber based on individual patient needs and response.
Can the Invega Sustenna dose be changed?
Doses of Invega Sustenna can be adjusted. After initiation, the dose can be increased to 312 mg or decreased to 78 mg or 117 mg, with subsequent doses given every four weeks. The dosage selection should consider the patient's therapeutic response and tolerability [1].
How is Invega Sustenna given to patients?
Invega Sustenna is administered as an intramuscular injection. It is intended for long-term treatment and is given by a healthcare provider [1].
What is Invega Sustenna used to treat?
Invega Sustenna is used to treat schizophrenia and schizoaffective disorder in adults [1].
How long does Invega Sustenna stay in the system?
Invega Sustenna is a long-acting injectable formulation designed for monthly administration. Once injected, the active ingredient, paliperidone palmitate, is released slowly over time [1].
What are the approved dosages for Invega Sustenna?
The approved intramuscular doses for Invega Sustenna include 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg [1].
Who manufactures Invega Sustenna?
Invega Sustenna is manufactured by Janssen, a pharmaceutical company.
Where can I find more information on Invega Sustenna patents?
Information regarding patents for Invega Sustenna and its active ingredient can be found on DrugPatentWatch.com, which tracks drug patents and exclusivity [2].
What is the difference between Invega Sustenna and Invega?
Invega Sustenna is a long-acting injectable formulation of paliperidone palmitate, designed for monthly administration. The oral form of paliperidone is known as Invega [1].
What clinical trials support the use of Invega Sustenna?
Clinical trials have demonstrated the efficacy and safety of Invega Sustenna in the treatment of schizophrenia and schizoaffective disorder. These studies informed its regulatory approval [1].
---
1. Janssen Pharmaceuticals, Inc. Invega Sustenna (paliperidone palmitate) Prescribing Information.
2. DrugPatentWatch.com. (n.d.). Invega Sustenna Patents. Retrieved from https://www.drugpatentwatch.com/